Table 4 Multiple-ordinal logistic regression models per clinical vignette

Belief of greater effectiveness of the new drug (vs. clinical equipoise)

0.74

0.60–0.92

0.008

–

–

–

Random allocation of study drugs (vs. medical decision)

1.05

.84–1.30

0.689

–

–

–

Public research funding (vs. research financed by a drug company)

1.29

1.04–1.60

0.022

–

–

–

Rare disease (vs. frequent, heart diseases)

–

–

–

0.90

0.71–1.14

0.387

Genetic analysis of specimens (vs. blood protein analyses)

–

–

–

1.19

0.94–1.50

0.147

Automatic reporting of test results to the participant (vs. only upon request)

–

–

–

1.12

0.89–1.42

0.334

Excellent/very good health status (vs. good/fair/poor)

0.78

0.60–1.02

0.065

1.42

1.07–1.89

0.016

Opinion on research (from “very negative” to “very positive”)

2.38

2.04–2.76

< 0.001

2.71

2.31–3.18

< 0.001

Previous participation in clinical studies (vs. no participation)

1.48

1.14–1.91

0.003

1.45

1.10–1.90

0.008

Blood or organ donor (vs. not)

1.51

1.21–1.88

< 0.001

2.16

1.70–2.74

< 0.001